Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility, the company announced on June 18, 2026. The facility is expected to be the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents, potentially transforming the market for medical imaging drugs.
The company is conducting a comprehensive analysis of candidate sites based on criteria including proximity to iodine brine sources, logistics, infrastructure, access to skilled labor, and government incentive packages. Strong candidate locations have been identified in Oklahoma and Texas, with key advantages such as proximity to Voyageur's iodine extraction initiatives in Oklahoma's Anadarko Basin, robust transportation infrastructure, and access to skilled labor and municipal water supply.
Voyageur's facility will receive concentrated iodine liquor from its Oklahoma brine operations and high-purity barite from the Frances Creek project. Unlike conventional manufacturers that rely on imported iodine flakes or intermediates, this integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading into USP-grade material and sterile injectable manufacturing. According to management, this vertical integration is expected to deliver industry-leading production costs and superior supply security for U.S. hospitals, government customers, and international distribution.
Key project highlights include the creation of 150–250 direct high-skilled jobs in manufacturing, engineering, quality assurance, laboratory, and operations, along with substantial indirect employment through construction and suppliers. The facility is expected to generate significant annual economic activity and major local tax revenue once at full scale. Voyageur plans to collaborate with post-secondary institutions to establish pharmaceutical training programs, co-op placements, and talent pipelines in chemical engineering and pharmaceutical sciences.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: "This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. The jurisdiction that provides Voyageur with the most significant incentive package will secure this transformative project and its substantial long-term economic benefits."
Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing, regulatory approvals, and other customary conditions. This announcement builds on Voyageur's ongoing collaboration with Bayer and recent advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use. The company continues to work closely with economic development corporations and state/federal partners to advance incentives and permitting.
Management believes the project aligns with U.S. priorities for domestic critical and strategic minerals, pharmaceutical onshoring of strategic drugs, and rural economic development. For more information, visit Voyageur Pharmaceuticals.
